

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/TB229BBCCA14EN.html>

Date: March 2022

Pages: 216

Price: US\$ 3,500.00 (Single User License)

ID: TB229BBCCA14EN

Abstracts

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Janus kinase 2 is a non-receptor tyrosine kinase. It is involved in various processes such as cell growth, development, differentiation, or histone modifications. It mediates essential signaling events in both innate and adaptive immunity. It plays a pivotal role in signal transduction via its association with type I receptors such as growth hormone, prolactin, leptin, erythropoietin, thrombopoietin or type II receptors including IFN-alpha, IFN-beta, IFN-gamma, and multiple interleukins. It plays a role in cell cycle by phosphorylating CDKN1B.

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) pipeline Target constitutes close to 36 molecules. Out of which approximately 26 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Archived (Marketed), Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 1, 6, 5, 2, 7 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 5 and 5 molecules, respectively.

Report covers products from therapy areas Oncology, Immunology, Dermatology, Respiratory, Infectious Disease, Hematological Disorders, Metabolic Disorders, Musculoskeletal Disorders, Cardiovascular, Central Nervous System, Genetic Disorders, Genito Urinary System And Sex Hormones, Ophthalmology and Women's Health which include indications Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Graft Versus Host Disease (GVHD), Rheumatoid Arthritis, Alopecia Areata, Atopic Dermatitis (Atopic Eczema), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Autoimmune Disorders, Coronavirus Disease 2019 (COVID-19), Glioblastoma Multiforme (GBM), Inflammation, Myelodysplastic Syndrome, Asthma, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Chronic Myelomonocytic Leukemia (CMML), Dermatitis (Eczema), Essential Thrombocythemia, Head And Neck Cancer, Hemophagocytic Lymphohistiocytosis, Leukemia, Peripheral T-Cell Lymphomas (PTCL), Plaque Psoriasis (Psoriasis Vulgaris), Polycythemia Vera, Sicca Syndrome (Sjogren), Solid Tumor, Unspecified Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Respiratory Distress Syndrome, Aicardi-Goutieres Syndrome (AGS), Allergies, Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Anaplastic Astrocytoma, Anaplastic Large Cell Lymphoma (ALCL), Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Angiosarcoma, Ankylosing Spondylitis (Bekhterev's Disease), Auto Inflammatory Disease, Breast Hyperplasia, Bronchiolitis Obliterans, Central Nervous System (CNS) Tumor, Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE), Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis), Chronic Kidney Disease (Chronic Renal Failure), Chronic Lymphocytic Leukemia (CLL), Chronic Obstructive Pulmonary Disease (COPD), Colorectal Cancer, Coronavirus Disease 2019 (COVID-19) Associated Cytokine Release Syndrome, Cutaneous T-Cell Lymphoma, Diabetic Macular Edema, Diffuse Large B-Cell Lymphoma, Endometrial Cancer, Epstein-Barr Virus (HHV-4) Infections, Focal Segmental Glomerulosclerosis (FSGS), Gallbladder Cancer, Gastrointestinal Tract Cancer, Giant Cell Arteritis (Temporal Arteritis/Cranial Arteritis/Horton Disease), Gliosarcoma, Hand Dermatitis, Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, Hematopoietic Stem Cell Transplantation, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Hypereosinophilic Syndrome, Hypopharyngeal Cancer, Idiopathic Pulmonary Fibrosis, Juvenile Arthritis, Keratoconjunctivitis Sicca (Dry Eye), Laryngeal Cancer, Lipodystrophy (Lipoatrophy), Liver Cancer, Melanoma, Mild Cognitive Impairment, Mycosis Fungoides, Myeloproliferative Disorders, Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Pancreatic Cancer, Pediatric Diffuse Intrinsic Pontine Glioma, Pneumonia, Polymyalgia Rheumatica (PMR), Prurigo, Psoriasis, Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed

Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Renal Cell Carcinoma, Salivary Gland Cancer, Secondary Myelofibrosis, Sezary Syndrome, Soft Tissue Sarcoma, Squamous Cell Carcinoma, Systemic Idiopathic Juvenile Arthritis, Systemic Sclerosis (Scleroderma), Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease), Thrombocythemia Myelofibrosis, Thyroid Cancer, Triple-Negative Breast Cancer (TNBC), Uterine Cancer and Vitiligo.

The latest report Tyrosine Protein Kinase JAK2 - Drugs In Development, 2022, outlays comprehensive information on the Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2)

The report reviews Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects

The report assesses Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Overview

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Therapeutics
Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Therapeutics
Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Companies
Involved in Therapeutics Development

Bristol-Myers Squibb Co

Chengdu Zenitar Biomedical Technology Co Ltd

Concert Pharmaceuticals Inc

Cothera Bioscience Pty Ltd

CTI BioPharma Corp

Eli Lilly and Co

Hangzhou East China Pharmaceutical Group Co Ltd

HK inno.N Corp

Incyte Corp

Japan Tobacco Inc

Kinaset Therapeutics Inc

Merck & Co Inc

Novartis AG

NS Pharma Inc

OHM Oncology

Pfizer Inc

Shanghai Xunhe Pharmaceutical Technology Co Ltd

Sichuan Kelun Bio-Tech Pharmaceutical Co Ltd

Sierra Oncology Inc

Sincere Pharmaceutical Group Ltd

Sino Biopharmaceutical Ltd
Suzhou Zelgen Biopharmaceutical Co Ltd
Theravance Biopharma Inc
Turning Point Therapeutics Inc
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Drug Profiles
A-223 - Drug Profile
Product Description
Mechanism Of Action
baricitinib - Drug Profile
Product Description
Mechanism Of Action
History of Events
CHZ-868 - Drug Profile
Product Description
Mechanism Of Action
CJ-15314 - Drug Profile
Product Description
Mechanism Of Action
History of Events
delgocitinib - Drug Profile
Product Description
Mechanism Of Action
History of Events
deuruxolitinib phosphate - Drug Profile
Product Description
Mechanism Of Action
History of Events
fedratinib - Drug Profile
Product Description
Mechanism Of Action
History of Events
filgotinib maleate - Drug Profile
Product Description
Mechanism Of Action
FLLL-12 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ilginatinib - Drug Profile

Product Description
Mechanism Of Action
History of Events
jaktinib hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
MA-2014 - Drug Profile
Product Description
Mechanism Of Action
momelotinib dihydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
OB-756 - Drug Profile
Product Description
Mechanism Of Action
OHM-581 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Opzelura - Drug Profile
Product Description
Mechanism Of Action
History of Events
pacritinib - Drug Profile
Product Description
Mechanism Of Action
History of Events
repotrectinib - Drug Profile
Product Description
Mechanism Of Action
History of Events
ruxolitinib phosphate - Drug Profile
Product Description
Mechanism Of Action
History of Events
SAR-317461 - Drug Profile
Product Description

Mechanism Of Action

History of Events

Small Molecule to Inhibit AURKA, EGFR and JAK2 for Gastrointestinal Tract Cancer -
Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Inhibit JAK1, JAK2 and TYK2 for Diabetic Macular Edema - Drug
Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Inhibit JAK1, JAK2, JAK3 and TYK2 for Asthma - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Inhibit JAK1, JAK2, JAK3 and TYK2 for Rheumatoid Arthritis - Drug
Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Inhibit JAK2 for Autoimmune Disorders and Unspecified Cancer -
Drug Profile

Product Description

Mechanism Of Action

Small Molecule to Inhibit JAK2 for Leukemia - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit BRD4 and JAK2 for Myelofibrosis - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit JAK1, JAK2, JAK3 and TYK2 for Dermatology - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Inhibit JAK2 and FLT3 for Myelofibrosis and Acute Myeloid
Leukemia - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Inhibit JAK2 and JAK3 for Immunology and Oncology - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Inhibit JAK2 for Inflammation and Oncology - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Inhibit JAK2 for Myelofibrosis - Drug Profile

Product Description

Mechanism Of Action

Small Molecule to Inhibit JAK 1 and JAK 2 for Inflammation - Drug Profile

Product Description

Mechanism Of Action

History of Events

TQ-05105 - Drug Profile

Product Description

Mechanism Of Action

History of Events

VR-588 - Drug Profile

Product Description

Mechanism Of Action

History of Events

zotiraciclib citrate - Drug Profile

Product Description

Mechanism Of Action

History of Events

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Dormant Products

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Discontinued Products

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Product Development Milestones

Featured News & Press Releases

Mar 07, 2022: Another lifesaving COVID-19 drug identified

Mar 04, 2022: VONJO (pacritinib) now approved for the treatment of adults with intermediate or high-risk primary or secondary myelofibrosis with a platelet count below 50 x 10⁹/L

Mar 01, 2022: DRI Healthcare Trust comments on FDA approval of VONJOTM (pacritinib)

Feb 28, 2022: CTI BioPharma announces FDA accelerated approval of VONJO (pacritinib) for the treatment of adult patients with Myelofibrosis and Thrombocytopenia

Feb 17, 2022: Zai Lab announces breakthrough therapy designation granted for Repotrectinib in China

Feb 17, 2022: WHO recommends Baricitinib for Covid-19

Jan 28, 2022: Updates on OLUMIANT (baricitinib) Phase 3 lupus program and FDA review for atopic dermatitis

Jan 25, 2022: Sierra Oncology provides financial update to support the future commercialization of momelotinib

Jan 25, 2022: Sierra Oncology announces momelotinib achieved statistically significant benefit on symptoms, anemia and splenic size in the pivotal MOMENTUM study for myelofibrosis

Jan 19, 2022: Momelotinib review article published in Journal of Hematology & Oncology highlights importance of anemia benefit for Myelofibrosis Patients

Jan 18, 2022: Sierra Oncology updates topline data timing for pivotal phase 3 trial of momelotinib in myelofibrosis

Jan 17, 2022: MSF responds to latest WHO recommendation for COVID-19 medicine baricitinib

Jan 14, 2022: WHO recommends Eli Lilly drug to treat COVID-19

Jan 04, 2022: Concert Pharmaceuticals completes enrollment in THRIVE-AA2 phase 3 clinical trial evaluating CTP-543 for Alopecia Areata

Dec 14, 2021: Incyte announces acceptance and Priority Review of sNDA for ruxolitinib cream (Opzelura) as a treatment for patients with vitiligo

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indications, 2022

Number of Products under Development by Indications, 2022 (Contd..1)

Number of Products under Development by Indications, 2022 (Contd..2)

Number of Products under Development by Indications, 2022 (Contd..3)

Number of Products under Development by Indications, 2022 (Contd..4)

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Products under Development by Companies, 2022 (Contd..3)

Products under Development by Companies, 2022 (Contd..4)

Products under Development by Companies, 2022 (Contd..5)

Products under Development by Companies, 2022 (Contd..6)

Products under Development by Companies, 2022 (Contd..7)

Products under Development by Companies, 2022 (Contd..8)

Products under Development by Companies, 2022 (Contd..9)

Products under Development by Companies, 2022 (Contd..10)

Number of Products under Investigation by Universities/Institutes, 2022

Products under Investigation by Universities/Institutes, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by Bristol-Myers Squibb Co, 2022

Pipeline by Chengdu Zenitar Biomedical Technology Co Ltd, 2022

Pipeline by Concert Pharmaceuticals Inc, 2022

Pipeline by Cothera Bioscience Pty Ltd, 2022

Pipeline by CTI BioPharma Corp, 2022

Pipeline by Eli Lilly and Co, 2022

Pipeline by Hangzhou East China Pharmaceutical Group Co Ltd, 2022

Pipeline by HK inno.N Corp, 2022

Pipeline by Incyte Corp, 2022

Pipeline by Japan Tobacco Inc, 2022

Pipeline by Kinaset Therapeutics Inc, 2022

Pipeline by Merck & Co Inc, 2022
Pipeline by Novartis AG, 2022
Pipeline by NS Pharma Inc, 2022
Pipeline by OHM Oncology, 2022
Pipeline by Pfizer Inc, 2022
Pipeline by Shanghai Xunhe Pharmaceutical Technology Co Ltd, 2022
Pipeline by Sichuan Kelun Bio-Tech Pharmaceutical Co Ltd, 2022
Pipeline by Sierra Oncology Inc, 2022
Pipeline by Simcere Pharmaceutical Group Ltd, 2022
Pipeline by Sino Biopharmaceutical Ltd, 2022
Pipeline by Suzhou Zelgen Biopharmaceutical Co Ltd, 2022
Pipeline by Theravance Biopharma Inc, 2022
Pipeline by Turning Point Therapeutics Inc, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Dormant Products, 2022 (Contd..2)
Dormant Products, 2022 (Contd..3)
Dormant Products, 2022 (Contd..4)
Dormant Products, 2022 (Contd..5)
Dormant Products, 2022 (Contd..6)
Discontinued Products, 2022
Discontinued Products, 2022 (Contd..1)

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

I would like to order

Product name: Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/TB229BBCCA14EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/TB229BBCCA14EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970